Replies to post #796 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Looks like a 10% share of new Rx’s ought to be doable by summer.

[go seek]

what would 20% of total HBV sales in the world be worth (for Idenix)?

and do you believe 20% is doable for Idenix in 2008?

[go seek]

Tyzeka prescriptions

4/13: 61 NRx, 135 TRx; 2.9% new, 1.9% total
04/6: 82 NRx, 137 TRx;
3/30: 87 NRx, 142 TRx; 3.9% new, 2.0% total
3/23: 55 NRx.., 90 TRx; 2.7% new, 1.3% total
2/23: 59 NRx.., 92 TRx; 3.1% new, 1.4% total
02/9: 55 NRx.., 83 TRx; 2.6% new, 1.2% total
1/26: 41 NRx.., 60 TRx; 2.0% new, 0.9% total

The "new" figure refers to Tyzeka’s market share in the given week among new prescriptions for all HBV drugs.

The "total" figure refers to Tyzeka’s market share in the given week among total prescriptions—new and refills—for all HBV drugs.

For a recently-launched drug such as Tyzeka, the market share of new prescriptions is a more useful gauge than the market share of total prescriptions.